Compare OSW & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | AAPG |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Bahamas | China |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2019 | N/A |
| Metric | OSW | AAPG |
|---|---|---|
| Price | $22.26 | $24.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $25.00 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $961,001,000.00 | N/A |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $7.99 | $368.64 |
| P/E Ratio | $31.62 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $14.21 | $17.56 |
| 52 Week High | $23.54 | $48.45 |
| Indicator | OSW | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 45.57 |
| Support Level | $20.74 | $23.06 |
| Resistance Level | $22.93 | $26.55 |
| Average True Range (ATR) | 0.99 | 0.83 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 58.97 | 54.14 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.